High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: Associated clinical and economic outcomes in real-world practice

Dermatology

Volumn 220, Issue 2, 2010, Pages 128-137

  Saurat, Jean Hilaire ^a   Guérin, Annie ^b   Yu, Andrew P ^b   Latremouille Viau, Dominick ^b   Wu, Eric Q ^b   Gupta, Shiraz R ^c   Bao, Yanjun ^c   Mulani, Parvez M ^c  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b ANALYSIS GROUP   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

Cyclosporine; Drug interactions; Health care costs; Methotrexate; Psoriasis; Tumor necrosis factor

Indexed keywords

ADAPALENE; ALITRETINOIN; AMPHOTERICIN; ANTIBIOTIC AGENT; AZATHIOPRINE; BEXAROTENE; CHLORAMPHENICOL; CYCLOSPORIN; ETRETIN; ETRETINATE; FLUCONAZOLE; GENTAMICIN; ISOTRETINOIN; KETOCONAZOLE; MELPHALAN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN DERIVATIVE; PHENYLBUTAZONE; PHENYTOIN; QUINUPRISTIN; RETINOIC ACID; RETINOL; SALICYLIC ACID DERIVATIVE; SULFONAMIDE; TAZAROTENE; TETRACYCLINE; THEOPHYLLINE; TRIMETHOPRIM; UNINDEXED DRUG;

ADULT; ARTICLE; BLOOD TOXICITY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG INTERACTION; EMERGENCY WARD; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL PATIENT; HUMAN; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; POLYPHARMACY; PRIORITY JOURNAL; PSORIASIS; RISK FACTOR;

AGED; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOSPORINE; DRUG INTERACTIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MANAGED CARE PROGRAMS; METHOTREXATE; MIDDLE AGED; PREVALENCE; PSORIASIS; RETINOIDS;

EID: 77949270344     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000275198     Document Type: Article

References (33)

1. Morse RM, Perry HO, Hurt RD: Alcoholism and psoriasis. Alcohol Clin Exp Res 1985;9:396-399.
2. Swanbeck G, Inerot A, Martinsson T, Wahlström J: A population genetic study of psoriasis. Br J Dermatol 1994;131:32-39.
3. Naldi L, Chatenoud L, Linder D, Belloni Fortina A, Peserico A, Virgili AR, Bruni PL, Ingordo V, Lo Scocco G, Solaroli C, Schena D, Barba A, Di Landro A, Pezzarossa E, Arcangeli F, Gianni C, Betti R, Carli P, Farris A, Barabino GF, La Vecchia C: Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005;125:61-67.
4. Schmitt JM, Ford DE: Work limitations and productivity loss are associated with healthrelated quality of life but not with clinical severity in patients with psoriasis. Dermatology 2006;213:102-110.
5. McClure SL, Valentine J, Gordon KB: Comparative tolerability of systemic treatments for plaque-type psoriasis. Drug Saf 2002;25:913-927.
6. US Food and Drug Administration: Methotrexate sodium tablet and solution for injection. http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/index.cfm (accessed March 27, 2009).
7. US Food and Drug Administration: Cyclosporine oral solution and soft capsules. http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/index.cfm (accessed March 27, 2009).
8. Mrowietz U, Elder JT, Barker J: The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Arch Dermatol Res 2006;298:309-319.
9. Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J: Association between psoriasis and the metabolic syndrome: a cross-sectional study. Dermatology 2008;216:152-155.
10. Gottlieb AB, Chao C, Dann F: Psoriasis comorbidities. J Dermatol Treat 2008;19:5-21.
11. Gerdes S, Zahl VA, Knopf H, Weichenthal M, Mrowietz U: Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis. Br J Dermatol 2008;159:1116-1123.
12. Yosipovitch G, Tang MB: Practical management of psoriasis in the elderly: epidemiology, clinical aspects, quality of life, patient education and treatment options. Drugs Aging 2002;19:847-863.
13. US Department of Health and Human Services: International Classification of Diseases, Ninth Revision, Clinical Modification, ed 4. Washington, US Government Printing Office, 1991.
14. Elixhauser A, Steiner C, Kruzikas D: Comorbidity software. HCUP Methods Series Report No 2004-1. US Agency for Healthcare Research and Quality. 2004. http://www.hcup-us.ahrq.gov/reports/Comorbidity.Software.Documentation.Final. pdf (accessed March 27, 2009).
15. Daly HM, Scott GL, Boyle J, Roberts CJ: Methotrexate toxicity precipitated by azapropazone. Br J Dermatol 1986;114:733-735.
16. Larsen FG, Nielsen-Kudsk F, Jakobsen P, Schrøder H, Kragballe K: Interaction of etretinate with methotrexate pharmacokinetics in psoriatic patients. J Clin Pharmacol 1990;30:802-807.
17. Casserly CM, Stange KC, Chren MM: Severe megaloblastic anemia in a patient receiving low-dose methotrexate for psoriasis. J Am Acad Dermatol 1993;29:477-480.
18. National Psoriasis Foundation: Cyclosporine. http://www.psoriasis.org/ treatment/psoriasis/systemics/cyclosporine.php (accessed March 27, 2009).
19. Aronoff GR: Nonsteroidal anti-inflammatory drug induced renal syndromes. J Ky Med Assoc 1992;90:336-339.
20. Laine L: Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001;120:594-606.
21. Gooch K, Culleton BF, Manns BJ, Zhang J, Alfonso H, Tonelli M, et al: NSAID use and progression of chronic kidney disease. Am J Med 2007;120:280.e1-280.e7.
22. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000;43:1905-1915.
23. Thomas DR, Dover JS, Camp RD: Pancytopenia induced by the interaction between methotrexate and trimethoprim-sulfa-methoxazole. J Am Acad Dermatol 1987;17:1055-1056.
24. Abel EA, Farber EM: Pancytopenia following low-dose methotrexate therapy. JAMA 1988;259:3612.
25. Elkayam O, Yaron M, Zhukovsky G, Segal R, Caspi D: Toxicity profile of dual methotrexate combinations with gold, hydroxychloroquine, sulphasalazine and minocycline in rheumatoid arthritis patients. Rheumatol Int 1997;17:49-53.
26. Caca-Biljanovska NG, V'lckova-Laskoska MT: Management of guttate and generalized psoriasis vulgaris: prospective randomized study. Croat Med J 2002;43:707-712.
27. Dogan B, Karabudak O, Harmanyeri Y: Antistreptococcal treatment of guttate psoriasis: a controlled study. Int J Dermatol 2008;47:950-952.
28. Saxena VN, Dogra J: Long-term use of penicillin for the treatment of chronic plaque psoriasis. Eur J Dermatol 2005;15:359-362.
29. Sander HM, Morris LF, Phillips CM, Harrison PE, Menter A: The annual cost of psoriasis. J Am Acad Dermatol 1993;28:422-425.
30. Crown WH, Bresnahan BW, Orsini LS, Kennedy S, Leonardi C: The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US. Curr Med Res Opin 2004;20:1929-1936.
31. Khachemoune A, Phillips TJ: Current treatment options in psoriasis. Hosp Pract (Minneap) 2000;35:93-96, 101-104, 107.
32. Jeffes EW 3rd, Weinstein GD: Methotrexate and other chemotherapeutic agents used to treat psoriasis. Dermatol Clin 1995;13:875-890.
33. Bhosle MJ, Feldman SR, Camacho FT, Timothy Whitmire J, Nahata MC, Balkrishnan R: Medication adherence and health care costs associated with biologics in Medicaid-enrolled patients with psoriasis. J Dermatol Treat 2006;17:294-301.